发明名称 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS
摘要 The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
申请公布号 WO0035887(A2) 申请公布日期 2000.06.22
申请号 WO1999US30311 申请日期 1999.12.17
申请人 DU PONT PHARMACEUTICALS COMPANY 发明人 CHEESMAN, EDWARD, H.;SWORIN, MICHAEL;RAJOPADHYEM, MILIND
分类号 A61K49/00;A61K51/04;C07D233/54;C07D401/12;C07D401/14;C07D403/12;C07D403/14;C07K5/02;C07K5/083;C07K5/097;C07K5/103;C07K5/117;C07K7/02;C07K7/06;C07K7/64;C07K9/00;(IPC1-7):C07D243/14;C07D235/24;C07D239/02;C07D213/02;C07C279/18 主分类号 A61K49/00
代理机构 代理人
主权项
地址